Sign up to save your data!
Some tips to help get started:
Processing...
There are 420 active trials for advanced/metastatic non-small cell lung cancer. Click on a trial to see more information.
420 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors (including IDH-wildtype glioblastoma) harboring MTAP loss who have progressed on standard therapy, and tests TNG456, a selective, brain-penetrant PRMT5 inhibitor, as monotherapy or in combination with abemaciclib (CDK4/6 inhibitor). Eligible patients must have measurable disease, good performance status, and adequate organ function.
ClinicalTrials.gov ID: NCT06810544
HealthScout AI summary: This trial enrolls adults with advanced, unresectable or metastatic solid tumors harboring any KRAS mutation who have progressed on or declined standard therapies; patients receive ALTA3263, an oral KRAS isoform-selective inhibitor that targets both active and inactive KRAS states and is designed to inhibit over 90% of known KRAS mutations, including G12D, G12V, and G12C. Prior KRAS inhibitor therapy is generally excluded.
ClinicalTrials.gov ID: NCT06835569
HealthScout AI summary: This trial is enrolling adults with advanced or metastatic solid tumors, especially those with MET alterations, including NSCLC with METex14 mutations, to receive VERT-002, a first-in-class monoclonal antibody degrader of c-MET administered intravenously every 2 weeks. Patients must have limited prior therapy options and no available curative treatments.
ClinicalTrials.gov ID: NCT06669117
HealthScout AI summary: This trial enrolls adults with metastatic HR+/HER2- breast cancer and other advanced solid tumors likely dependent on CDK4 activity, who have progressed on or are intolerant to standard therapies, to receive the investigational CDK4 inhibitor BGB-43395 (a selective CDK4 inhibitor with minimal CDK6 inhibition) as monotherapy or combined with fulvestrant or letrozole. Prior CDK4/6 inhibitor exposure is permitted and sometimes required, but prior selective CDK4 inhibitors are excluded.
ClinicalTrials.gov ID: NCT06120283
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring KRAS mutations (including NSCLC, CRC, and PDAC) who have progressed after standard therapies, testing the investigational oral panKRAS inhibitor PF-07934040 (blocks RAF binding to KRAS) as monotherapy and in combination with standard regimens. Eligible patients must have limited treatment options; certain arms allow first-line patients for combination therapies.
ClinicalTrials.gov ID: NCT06447662
HealthScout AI summary: This trial enrolls adults with advanced, recurrent, or metastatic solid tumors (including platinum-resistant ovarian cancer, triple-negative breast cancer, squamous cell carcinoma of the anus or head and neck, non-small cell lung cancer, and uterine serous cancer) who have progressed on all standard therapies, to receive SMP-3124LP, a novel liposomal CHK1 inhibitor given by intravenous infusion. SMP-3124LP targets the DNA damage response pathway and is being assessed for safety, tolerability, and preliminary efficacy.
ClinicalTrials.gov ID: NCT06526819
HealthScout AI summary: Adults with advanced or metastatic non-small cell lung cancer harboring EGFR activating mutations who have progressed on or are ineligible for standard EGFR-TKI therapies (including cases with resistance mutations like C797S) may enroll to receive BG-60366, an oral chimeric degradation activation compound that selectively degrades mutant EGFR. Prior small cell transformation, symptomatic CNS metastases, previous fourth-generation EGFR-TKIs, and significant interstitial lung disease are exclusion criteria.
ClinicalTrials.gov ID: NCT06685718
HealthScout AI summary: Adults with advanced or metastatic solid tumors (including NSCLC, triple-negative breast cancer, head and neck squamous cell carcinoma, gastric cancer, or melanoma), particularly those refractory or relapsed after immune checkpoint inhibitors, will receive the investigational anti-CCR8 monoclonal antibody BAY3375968 (which depletes tumor-infiltrating Tregs) as monotherapy or combined with pembrolizumab. Eligible patients must have measurable disease, ECOG 0-1, and be willing to undergo tumor biopsies.
ClinicalTrials.gov ID: NCT05537740
HealthScout AI summary: This trial enrolls adults with advanced or metastatic GPC3-expressing solid tumors (including hepatocellular carcinoma, AFP-producing gastric cancer, extragonadal yolk sac tumors, non-dysgerminomas, or GPC3-positive squamous NSCLC) who have ECOG 0-1. Patients will receive the investigational bispecific antibody BGB-B2033 (targeting GPC3 and 4-1BB) alone or combined with the anti-PD-1 antibody tislelizumab.
ClinicalTrials.gov ID: NCT06427941
HealthScout AI summary: This trial enrolls adults with recurrent, unresectable, locally advanced, or metastatic solid tumors—including colorectal, pancreatic, NSCLC, ovarian cancer, mesothelioma, and others—that express mesothelin (MSLN) and have lost HLA-A*02 expression, who are heterozygous for HLA-A*02. Eligible patients receive a single infusion of A2B694, an autologous CAR T-cell therapy engineered with a logic-gated Tmod system to selectively target MSLN-positive, HLA-A*02-negative tumor cells.
ClinicalTrials.gov ID: NCT06051695
